776 related articles for article (PubMed ID: 28355462)
1. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
2. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
Lortholary O; Fernández-Ruiz M; Perfect JR
J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
[TBL] [Abstract][Full Text] [Related]
3. Invasive mould infections in the ICU setting: complexities and solutions.
Bassetti M; Bouza E
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
[TBL] [Abstract][Full Text] [Related]
4. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.
Jenks JD; Reed SL; Seidel D; Koehler P; Cornely OA; Mehta SR; Hoenigl M
Int J Antimicrob Agents; 2018 Nov; 52(5):706-712. PubMed ID: 30099056
[TBL] [Abstract][Full Text] [Related]
5. Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients.
Negri CE; Gonçalves SS; Sousa ACP; Bergamasco MD; Martino MDV; Queiroz-Telles F; Aquino VR; Castro PTO; Hagen F; Meis JF; Colombo AL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893772
[No Abstract] [Full Text] [Related]
6. Changing epidemiology of rare mould infections: implications for therapy.
Malani AN; Kauffman CA
Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951
[TBL] [Abstract][Full Text] [Related]
7. [State of the art in invasive diseases by filamentous fungi].
Pemán J; Quindós G
Rev Iberoam Micol; 2014; 31(4):213-8. PubMed ID: 25449676
[TBL] [Abstract][Full Text] [Related]
8. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.
Bhatti Z; Shaukat A; Almyroudis NG; Segal BH
Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Challenges of Non-
Lamoth F; Kontoyiannis DP
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481441
[TBL] [Abstract][Full Text] [Related]
11. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
12. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi.
Koehler P; Tacke D; Cornely OA
Crit Rev Microbiol; 2016; 42(1):158-71. PubMed ID: 24809926
[TBL] [Abstract][Full Text] [Related]
13. Association of pretreatment with antifungal medication and fungal resistance in the mycotic ulcer treatment trial I.
Prajna NV; Prajna L; O'Brien KS; Sun CQ; Acharya N; Lietman TM; Rose-Nussbaumer J;
JAMA Ophthalmol; 2015 Oct; 133(10):1210-1. PubMed ID: 26110254
[No Abstract] [Full Text] [Related]
14. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
15. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?
Snelders E; Melchers WJ; Verweij PE
Future Microbiol; 2011 Mar; 6(3):335-47. PubMed ID: 21449843
[TBL] [Abstract][Full Text] [Related]
16. Molecular bases of antifungal resistance in filamentous fungi.
Sharma C; Chowdhary A
Int J Antimicrob Agents; 2017 Nov; 50(5):607-616. PubMed ID: 28705674
[TBL] [Abstract][Full Text] [Related]
17. In vitro combination of voriconazole and miltefosine against clinically relevant molds.
Imbert S; Palous M; Meyer I; Dannaoui E; Mazier D; Datry A; Fekkar A
Antimicrob Agents Chemother; 2014 Nov; 58(11):6996-8. PubMed ID: 25199776
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
[TBL] [Abstract][Full Text] [Related]
19. [Azole-resistant invasive aspergillosis].
van der Linden JW; Warris A; van der Meer JW; Bresters D; Melchers WJ; Verweij PE
Ned Tijdschr Geneeskd; 2009; 153():A765. PubMed ID: 20051169
[TBL] [Abstract][Full Text] [Related]
20. Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus.
Verweij PE; Kema GH; Zwaan B; Melchers WJ
Pest Manag Sci; 2013 Feb; 69(2):165-70. PubMed ID: 23109245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
